351 related articles for article (PubMed ID: 17183557)
1. Testosterone replacement for hypogonadism after treatment of early prostate cancer with brachytherapy.
Sarosdy MF
Cancer; 2007 Feb; 109(3):536-41. PubMed ID: 17183557
[TBL] [Abstract][Full Text] [Related]
2. Prostate Safety Events During Testosterone Replacement Therapy in Men With Hypogonadism: A Randomized Clinical Trial.
Bhasin S; Travison TG; Pencina KM; O'Leary M; Cunningham GR; Lincoff AM; Nissen SE; Lucia MS; Preston MA; Khera M; Khan N; Snabes MC; Li X; Tangen CM; Buhr KA; Thompson IM
JAMA Netw Open; 2023 Dec; 6(12):e2348692. PubMed ID: 38150256
[TBL] [Abstract][Full Text] [Related]
3. EMAS position statement: Testosterone replacement therapy in older men.
Kanakis GA; Pofi R; Goulis DG; Isidori AM; Armeni E; Erel CT; Fistonić I; Hillard T; Hirschberg AL; Meczekalski B; Mendoza N; Mueck AO; Simoncini T; Stute P; van Dijken D; Rees M; Lambrinoudaki I
Maturitas; 2023 Dec; 178():107854. PubMed ID: 37845136
[TBL] [Abstract][Full Text] [Related]
4. Testosterone replacement therapy for late-onset hypogonadism: current trends in Korea.
Ko YH; Kim JJ
Asian J Androl; 2011 Jul; 13(4):563-8. PubMed ID: 21572448
[TBL] [Abstract][Full Text] [Related]
5. Does testosterone replacement therapy increase the risk of conversion to treatment in patients with prostate cancer on active surveillance?
Daza J; Ahmad A; Shabir U; Jing Z; Shiekh M; Kauffman E; Guru KA; Hussein AA
Urol Oncol; 2023 Oct; 41(10):429.e1-429.e7. PubMed ID: 37423815
[TBL] [Abstract][Full Text] [Related]
6. Testosterone replacement therapy is not associated with increased prostate cancer incidence, prostate cancer-specific, or cardiovascular disease-specific mortality in Finnish men.
Siltari A; Murtola TJ; Kausz J; Talala K; Taari K; Tammela TL; Auvinen A
Acta Oncol; 2023 Dec; 62(12):1898-1904. PubMed ID: 37971326
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of Testosterone Replacement Therapy in Correcting Anemia in Men With Hypogonadism: A Randomized Clinical Trial.
Pencina KM; Travison TG; Artz AS; Lincoff AM; Nissen SE; Flevaris P; Chan A; Li X; Diegel SA; Wannemuehler K; Bhasin S
JAMA Netw Open; 2023 Oct; 6(10):e2340030. PubMed ID: 37889486
[TBL] [Abstract][Full Text] [Related]
8. Current state of practice regarding testosterone supplementation therapy in men with prostate cancer.
Kovac JR; Pan MM; Lipshultz LI; Lamb DJ
Steroids; 2014 Nov; 89():27-32. PubMed ID: 25072793
[TBL] [Abstract][Full Text] [Related]
9. The Impact of Hypogonadism on Surgical Outcomes Following Primary Urethroplasty: Analysis of a Large Multi-institutional Database.
Gabrielson AT; Galansky L; Shneyderman M; Cohen AJ
Urology; 2024 Mar; 185():116-123. PubMed ID: 38190864
[TBL] [Abstract][Full Text] [Related]
10. Untreated hypogonadism and testosterone replacement therapy in hypogonadal men are associated with a decreased risk of subsequent prostate cancer: a population-based study.
Asanad K; Horns JJ; Driggs N; Samplaski MK; Hotaling JM
Int J Impot Res; 2024 Jan; ():. PubMed ID: 38177194
[TBL] [Abstract][Full Text] [Related]
11. Testosterone Replacement Therapy and Risk of Favorable and Aggressive Prostate Cancer.
Loeb S; Folkvaljon Y; Damber JE; Alukal J; Lambe M; Stattin P
J Clin Oncol; 2017 May; 35(13):1430-1436. PubMed ID: 28447913
[TBL] [Abstract][Full Text] [Related]
12. The prevalence and demographic determinants of blood donors receiving testosterone replacement therapy at a large USA blood service organization.
Hazegh K; Bravo MD; Kamel H; Dumont L; Kanias T
Transfusion; 2020 May; 60(5):947-954. PubMed ID: 32176332
[TBL] [Abstract][Full Text] [Related]
13. Exogenous Testosterone Replacement Therapy Is Associated with Increased Risk for Vascular Graft Infections Among Hypogonadal Men.
Longwolf KJ; Johnson CE; Horns JJ; Hotaling JM; Brooke BS
Ann Vasc Surg; 2023 Nov; 97():113-120. PubMed ID: 37453467
[TBL] [Abstract][Full Text] [Related]
14. Shifting the Paradigm of Testosterone Replacement Therapy in Prostate Cancer.
Bell MA; Campbell JD; Joice G; Sopko NA; Burnett AL
World J Mens Health; 2018 May; 36(2):103-109. PubMed ID: 29623698
[TBL] [Abstract][Full Text] [Related]
15. Effects of Testosterone Replacement Therapy on Muscle Strength in Older Men with Low to Low-Normal Testosterone Levels: A Systematic Review and Meta-Analysis.
Lee TW; Kao PY; Chen YC; Wang ST
Gerontology; 2023; 69(10):1157-1166. PubMed ID: 37494893
[TBL] [Abstract][Full Text] [Related]
16. Do we have enough evidences that make you safe to treat a man with hypogonadism one year after a radical prostatectomy for prostate cancer? | Opinion: YES.
Torres LO
Int Braz J Urol; 2018; 44(1):4-7. PubMed ID: 29424506
[No Abstract] [Full Text] [Related]
17. Do we have enough evidences that make you safe to treat a man with hypogonadism one year after a radical prostatectomy for prostate cancer? | Opinion: Not Yet.
Wroclawski ML; Heldwein FL
Int Braz J Urol; 2018; 44(1):8-13. PubMed ID: 29424507
[No Abstract] [Full Text] [Related]
18. Metabolic effects of testosterone added to intensive lifestyle intervention in older men with obesity and hypogonadism.
Gonzalez-Gil AM; Barnouin Y; Celli A; Viola V; Villarreal MD; Duremdes Nava ML; Sciuk A; Qualls C; Armamento-Villareal R; Villareal DT
J Clin Endocrinol Metab; 2024 Apr; ():. PubMed ID: 38606934
[TBL] [Abstract][Full Text] [Related]
19. The benefits and risks of testosterone replacement therapy: a review.
Bassil N; Alkaade S; Morley JE
Ther Clin Risk Manag; 2009 Jun; 5(3):427-48. PubMed ID: 19707253
[TBL] [Abstract][Full Text] [Related]
20. Use of testosterone replacement therapy to treat long-COVID-related hypogonadism.
Amodeo A; Persani L; Bonomi M; Cangiano B
Endocrinol Diabetes Metab Case Rep; 2024 Jan; 2024(1):. PubMed ID: 38520748
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
